These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 35729230)

  • 1. CD73 downregulation by EGFR-targeted liposomal CD73 siRNA potentiates antitumor effect of liposomal doxorubicin in 4T1 tumor-bearing mice.
    Soleimani A; Mirzavi F; Nikoofal-Sahlabadi S; Nikpoor AR; Taghizadeh B; Barati M; Soukhtanloo M; Jaafari MR
    Sci Rep; 2022 Jun; 12(1):10423. PubMed ID: 35729230
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Blockade of CD73 using siRNA loaded chitosan lactate nanoparticles functionalized with TAT-hyaluronate enhances doxorubicin mediated cytotoxicity in cancer cells both in vitro and in vivo.
    Salehi Khesht AM; Karpisheh V; Sahami Gilan P; Melnikova LA; Olegovna Zekiy A; Mohammadi M; Hojjat-Farsangi M; Majidi Zolbanin N; Mahmoodpoor A; Hassannia H; Aghebati-Maleki L; Jafari R; Jadidi-Niaragh F
    Int J Biol Macromol; 2021 Sep; 186():849-863. PubMed ID: 34245737
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Downregulation of CD73 in 4T1 breast cancer cells through siRNA-loaded chitosan-lactate nanoparticles.
    Jadidi-Niaragh F; Atyabi F; Rastegari A; Mollarazi E; Kiani M; Razavi A; Yousefi M; Kheshtchin N; Hassannia H; Hadjati J; Shokri F
    Tumour Biol; 2016 Jun; 37(6):8403-12. PubMed ID: 26733167
    [TBL] [Abstract][Full Text] [Related]  

  • 4. GE11-Directed Functional Polymersomal Doxorubicin as an Advanced Alternative to Clinical Liposomal Formulation for Ovarian Cancer Treatment.
    Zou Y; Xia Y; Meng F; Zhang J; Zhong Z
    Mol Pharm; 2018 Sep; 15(9):3664-3671. PubMed ID: 29570299
    [TBL] [Abstract][Full Text] [Related]  

  • 5. GE11 peptide-conjugated nanoliposomes to enhance the combinational therapeutic efficacy of docetaxel and siRNA in laryngeal cancers.
    Xu WW; Liu DY; Cao YC; Wang XY
    Int J Nanomedicine; 2017; 12():6461-6470. PubMed ID: 28919747
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CD73 specific siRNA loaded chitosan lactate nanoparticles potentiate the antitumor effect of a dendritic cell vaccine in 4T1 breast cancer bearing mice.
    Jadidi-Niaragh F; Atyabi F; Rastegari A; Kheshtchin N; Arab S; Hassannia H; Ajami M; Mirsanei Z; Habibi S; Masoumi F; Noorbakhsh F; Shokri F; Hadjati J
    J Control Release; 2017 Jan; 246():46-59. PubMed ID: 27993599
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of a bone-targeted pH-sensitive liposomal formulation containing doxorubicin: physicochemical characterization, cytotoxicity, and biodistribution evaluation in a mouse model of bone metastasis.
    Ferreira Ddos S; Faria SD; Lopes SC; Teixeira CS; Malachias A; Magalhães-Paniago R; de Souza Filho JD; Oliveira BL; Guimarães AR; Caravan P; Ferreira LA; Alves RJ; Oliveira MC
    Int J Nanomedicine; 2016; 11():3737-51. PubMed ID: 27563241
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug release rate influences the pharmacokinetics, biodistribution, therapeutic activity, and toxicity of pegylated liposomal doxorubicin formulations in murine breast cancer.
    Charrois GJ; Allen TM
    Biochim Biophys Acta; 2004 May; 1663(1-2):167-77. PubMed ID: 15157619
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The impact of phospholipids with high transition temperature to enhance redox-sensitive liposomal doxorubicin efficacy in colon carcinoma model.
    Mirhadi E; Askarizadeh A; Farhoudi L; Mashreghi M; Behboodifar S; Alavizadeh SH; Arabi L; Jaafari MR
    Chem Phys Lipids; 2024 Jul; 261():105396. PubMed ID: 38621603
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CD73 promotes anthracycline resistance and poor prognosis in triple negative breast cancer.
    Loi S; Pommey S; Haibe-Kains B; Beavis PA; Darcy PK; Smyth MJ; Stagg J
    Proc Natl Acad Sci U S A; 2013 Jul; 110(27):11091-6. PubMed ID: 23776241
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improved drug delivery and therapeutic efficacy of PEgylated liposomal doxorubicin by targeting anti-HER2 peptide in murine breast tumor model.
    Zahmatkeshan M; Gheybi F; Rezayat SM; Jaafari MR
    Eur J Pharm Sci; 2016 Apr; 86():125-35. PubMed ID: 26972276
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-angiogenic effects of CD73-specific siRNA-loaded nanoparticles in breast cancer-bearing mice.
    Ghalamfarsa G; Rastegari A; Atyabi F; Hassannia H; Hojjat-Farsangi M; Ghanbari A; Anvari E; Mohammadi J; Azizi G; Masjedi A; Yousefi M; Yousefi B; Hadjati J; Jadidi-Niaragh F
    J Cell Physiol; 2018 Oct; 233(10):7165-7177. PubMed ID: 29741783
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Doxorubicin loaded liposomes for lung tumor targeting: in vivo cell line study in human lung cancer.
    Guo Y; Zhu Q; Shi J; Li Y; Fu D; Qiao D; Chen S; Yang Y; Wang Y
    J BUON; 2020; 25(3):1504-1511. PubMed ID: 32862597
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ultrasound-mediated cavitation enhances the delivery of an EGFR-targeting liposomal formulation designed for chemo-radionuclide therapy.
    Thomas E; Menon JU; Owen J; Skaripa-Koukelli I; Wallington S; Gray M; Mannaris C; Kersemans V; Allen D; Kinchesh P; Smart S; Carlisle R; Vallis KA
    Theranostics; 2019; 9(19):5595-5609. PubMed ID: 31534505
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Silencing tumor-intrinsic CD73 enhances the chemosensitivity of NSCLC and potentiates the anti-tumoral effects of cisplatin: An in vitro study.
    Baghbani E; Noorolyai S; Rahmani S; Shanehbandi D; Shadbad MA; Aghebati-Maleki L; Mokhtarzadeh A; Brunetti O; Fasano R; Silvestris N; Baradaran B
    Biomed Pharmacother; 2022 Jan; 145():112370. PubMed ID: 34862113
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeted Delivery of Doxorubicin Liposomes for Her-2+ Breast Cancer Treatment.
    Chowdhury N; Chaudhry S; Hall N; Olverson G; Zhang QJ; Mandal T; Dash S; Kundu A
    AAPS PharmSciTech; 2020 Jul; 21(6):202. PubMed ID: 32696338
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Engineered breast tumor targeting peptide ligand modified liposomal doxorubicin and the effect of peptide density on anticancer activity.
    Shahin M; Soudy R; Aliabadi HM; Kneteman N; Kaur K; Lavasanifar A
    Biomaterials; 2013 May; 34(16):4089-4097. PubMed ID: 23465829
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Study of FA12 peptide-modified PEGylated liposomal doxorubicin (PLD) as an effective ligand to target Muc1 in mice bearing C26 colon carcinoma: in silico, in vitro, and in vivo study.
    Biabangard A; Asoodeh A; Jaafari MR; Mashreghi M
    Expert Opin Drug Deliv; 2022 Dec; 19(12):1710-1724. PubMed ID: 36373415
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dual Mechanisms of Novel CD73-Targeted Antibody and Antibody-Drug Conjugate in Inhibiting Lung Tumor Growth and Promoting Antitumor Immune-Effector Function.
    Jin R; Liu L; Xing Y; Meng T; Ma L; Pei J; Cong Y; Zhang X; Ren Z; Wang X; Shen J; Yu K
    Mol Cancer Ther; 2020 Nov; 19(11):2340-2352. PubMed ID: 32943546
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of long-circulating cationic nanoparticle formulations consisting of a two-stage PEGylation step for the delivery of siRNA in a breast cancer tumor model.
    Ho EA; Osooly M; Strutt D; Masin D; Yang Y; Yan H; Bally M
    J Pharm Sci; 2013 Jan; 102(1):227-36. PubMed ID: 23132529
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.